CatalYm funding news – Munich-based CatalYm Secures $150 Million in Series D Round Funding
Jul 16, 2024 | By Startup Rise EU
![CatalYm secures $150 million in series D round funding. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund (“Forbion Growth”), Omega Funds and Gilde Healthcare.](https://startuprise.co.uk/wp-content/uploads/2024/07/Munich-based-CatalYm-Secures-150-Million-in-Series-D-Round-Funding.webp)
CatalYm secures $150 million in series D round funding. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund (“Forbion Growth”), Omega Funds and Gilde Healthcare.
SUMMARY
- Proceeds will expand visugromab’s late-stage clinical development into earlier lines of treatment including checkpoint naïve and second-line settings in randomized, controlled studies in select solid tumor indications.
- Round brings on board new international biotech investors, Canaan Partners, Bioqube Ventures, Omega Funds, Forbion Growth Fund and Gilde Healthcare to support direct path towards registration for visugromab
Existing investors Jeito Capital, Brandon Capital Partners, Novartis Venture Fund and Vesalius Biocapital III also participated in the round. The proceeds will fund the expansion of the company’s broad Phase 2b development of visugromab into randomized Phase 2b studies in select checkpoint naïve frontline and second-line treatment settings. Visugromab has already demonstrated outstanding anti-tumor activity in combination with checkpoint inhibitor treatment.
Read also - Adam Funding news – Czech-based Adam Secures €3 Million in late Seed Funding
Visugromab is a humanized monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15), which acts as a key regulator of immune resistance to cancer therapies. CatalYm recently reported impressive follow-up results from its ongoing “GDFATHER” Phase 1/2a trial (GDF-15 Antibody-mediaTed Human Effector Cell Relocation Phase 1/2a) (NCT04725474) in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 in Chicago.
RECOMMENDED FOR YOU
![recomd](https://startuprise.co.uk/wp-content/uploads/2024/07/UK-based-Huma-Secures-80-Million-in-Series-D-Round-Funding.webp)
Huma funding news – UK-based Huma Secures $80 Million in Series D Round Funding
Startup Rise EU
Jul 16, 2024
![recomd](https://startuprise.co.uk/wp-content/uploads/2023/10/Aarhus-based-Relewise-Secures-E800k-in-Pre-Seed-Funding.webp)
[Funding alert] Aarhus-based Relewise Secures €800k in Pre-Seed Funding
Startup Rise EU
Oct 13, 2023
![recomd](https://startuprise.co.uk/wp-content/uploads/2024/01/Amsterdam-based-Send-AI-Raises-E2.2Million-in-a-Pre-Seed-Round-Funding.webp)
[Funding alert] Amsterdam-based Send AI Raises €2.2Million in a Pre-Seed Round Funding
Startup Rise EU
Jan 27, 2024
The data showed that treatment with visugromab combined with the anti-PD-1 antibody, nivolumab achieves deep and durable anti-tumoral activity, including several complete responses in anti-PD-1/PD-L1 relapsed/refractory patients with non-small cell lung cancer (NSCLC), urothelial cancer (UC) or hepatocellular carcinoma (HCC).
Phil L’Huillier, Managing Director and Chief Executive Officer at CatalYm said, “This substantial raise and strong syndicate recognize our achievements as a company and emphasize the excellent results of visugromab and our broad Phase 2b clinical program. We continue to demonstrate visugromab’s potential to induce cancer remission depth and durability across multiple solid tumor indications emphasizing the substantial role visugromab could play in a novel anti-cancer therapy regimen, We are building significant momentum for CatalYm’s development strategy and look forward to the support of these high-profile new and existing international investors, who share our vision of breaking immunosuppressive barriers to improve therapeutic outcomes.”
In conjunction with the close of the financing, Colleen Cuffaro, Partner at Canaan, Jon Edwards, Managing Partner at Bioqube Ventures and Otello Stampacchia, Managing Director and Founder at Omega Funds, will join the CatalYm Board of Directors. Stefan Luzi, Partner at Gilde Healthcare will join as Board Observer.
Colleen Cuffaro, Partner at Canaan Partners said, “The recent data presented at ASCO highlight visugromab’s highly differentiated therapeutic profile and validate the ability of Phil and his team to expeditiously execute on the company’s clinical plan, As the company advances into expanded Phase 2b development, we are excited to provide our strategic guidance on the company’s trajectory toward changing the current treatment regimens for hard-to-treat solid tumor indications.”
Jon Edwards, Managing Partner at Bioqube Ventures added: “We were initially drawn to the exciting biology around GDF-15 and found CatalYm to be at the forefront of the field. We believe this approach has the potential to significantly increase durability and deepen responses, unlocking the full potential of I/O treatments. We are excited to support this fantastic team, and syndicate, in running robust clinical studies in a variety of promising indications.”
About CatalYm
CatalYm has identified GDF-15 as a key cancer therapy resistance mechanism and is developing it as safe and efficacious immune therapy for solid tumors. GDF-15, an immunosuppressant important for feto-maternal tolerance, is hijacked by cancer cells to evade immune system attack.
Visugromab, CatalYm’s lead antibody, has demonstrated durable anti-tumor efficacy with long-lasting objective responses in relapsed and refractory metastatic solid tumor patients in combination with anti-PD-1 treatment.
Recommended Stories for You
![story](https://startuprise.co.uk/wp-content/uploads/2023/11/Turin-based-Climatetech-Startup-CarpeCarbon-Secures-E1.7-Million-in-Pre-Seed-Funding-.webp)
[Funding alert] Turin-based Climatetech Startup CarpeCarbon Secures €1.7 Million in Pre-Seed Funding
Startup Rise EU Nov 15, 2023